Universitair Medisch Centrum Groningen
Universitair Medisch Centrum Groningen is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
Psilocybin therapy for Psychological Distress in Palliative Care Patients (PsyPal)
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Latest update
- Estimated end
- Not reported
The RHINOME study
Sponsor Region Hovedstaden
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
HOVON 176: Golcadomide (CC-99282) for relapsed and refractory primary large B-cell lymphoma of the central nervous system and secondary central nervous system lymphoma: a phase 2 study
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
HOVON 171 AML: A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens
Sponsor Haemato Oncology Foundation For Adults Netherlands
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.
Sponsor European Group for Research in Schizophrenia Stichting
- Start (EU)
- Not reported
- Latest update
- Estimated end
CANIDIAP; CANagliflozin In DIAlysis Patients
Sponsor Universitair Medisch Centrum Groningen
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitair Medisch Centrum Groningen?
The 2026-10-09 snapshot links Universitair Medisch Centrum Groningen to 9 distinct CTIS trials. Recorded services include Laboratory services, Statistical analysis, Biobanking, Clinical monitoring, among 14 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitair Medisch Centrum Groningen?
The most frequently recorded therapeutic areas are Haematological Malignancies, Respiratory, Neurology, Otolaryngology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitair Medisch Centrum Groningen conducted?
The linked trials record locations in 15 countries, including Netherlands, Denmark, Belgium, Czechia, Spain. These are trial locations, not confirmed office locations or countries where Universitair Medisch Centrum Groningen delivered services.
What can this page tell me about Universitair Medisch Centrum Groningen's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitair Medisch Centrum Groningen. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitair Medisch Centrum Groningen